Angiotensin-converting enzyme (ACE) inhibitors were found to be independently associated with reducing all-cause mortality in ...

ACE inhibitor use was associated with reduced all cause mortality in idiopathic pulmonary fibrosis in a matched real world ...

A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without ...

Among patients with idiopathic pulmonary fibrosis, the risk for all-cause mortality was significantly lower with vs. without angiotensin-converting enzyme inhibitor use started within 5 years before ...

Please provide your email address to receive an email when new articles are posted on . Within the studied cohort, males had a higher IPF death rate than females. Researchers observed eight industries ...

Antifibrotic therapy shows similar efficacy in familial and sporadic IPF, with no significant differences in survival or acute exacerbations. Because familial idiopathic pulmonary fibrosis is ...

A new large-scale real-world study has found that the use of angiotensin-converting enzyme (ACE) inhibitors may be associated with improved survival in patients with idiopathic pulmonary fibrosis (IPF ...

Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the ...

Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely compromises ...

University of South Florida pulmonologist Dr. Jose Herazo-Maya has focused his career on researching treatments for pulmonary fibrosis, a devastating and deadly lung disease. Pulmonary fibrosis in ...